-Carbolines were prepared from pyrido[4,3-b]-5H-indoles via Pd(0)-catalysed, stereo and regioselective allene/uridine allene insertion 3-and 5-component cascades. This versatile reaction sequence gives a range of structurally diverse carboline derivatives and tolerates a broad range of substrates. The power of this approach has been harnessed to produce -carboline based HDAC inhibitors.
Introduction
Interest in -and -carbolines (pyrido [4,3-b] -5H-indoles) and their analogues has increased considerably over the last decade primarily due to their wide ranging biological and pharmacological properties. [1] [2] [3] For instance, biologically activetetrahydrocarboline derivatives include the antihistamines Mebhydrolin (Diazoline) 9 1
and Dimebolin (Latrepirdine) 2, the latter system showing potential in the treatment of Alzheimer's disease and other neurodegenerative diseases. 4,5 Additionally, Flutroline 3 has been used in the treatment of schizophrenia, 7a and Tubastatin A 4 and its analogues have been shown to selectively inhibit histone deacetylase 6 (HDAC6), 8 and may hold promise in the treatment of certain cancers ( Figure 1 ).
Furthermore, a series of putative HDAC inhibitors bearing -and -carboline scaffolds has recently been patented for use as anti-cancer therapeutics by Grigg, 10 with the most promising candidates being AC148 (5) and AC190 (6) . An important requirement for biological activity within these systems appears to be the presence of a benzamide moiety, which is thought to bind to zinc ion present in the active site of the HDAC enzyme.
*corresponding authors: email c.w.g.fishwick@leeds.ac.uk and r.grigg@leeds.ac.uk Figure 1 . Biologically active carboline compounds.
We have previously described a powerful and versatile approach to a range of functionalised heterocycles based upon the use of a palladium-catalysed allene insertion multicomponent cascade. [11] [12] [13] [14] [15] As indicated above, we were able to utilise this chemistry to prepare novel carboline-based molecules, exemplified by AC190 6 that are showing promise as anticancer drug leads. Encouraged by the ease with which these systems could be obtained, we wished to further explore the scope of this approach to such biologically active carboline systems with a view to identifying additional examples of HDAC inhibitors of therapeutic potential. Herein, we describe the application of this methodology to the production of a range oftetrahydrocarboline-based derivatives.
Results and discussion
The -tetrahydrocarboline 7 was used along with a series of aryl or heteroaryl iodides and allene or uridine allene to generate a wide range of structurally diverse compounds via 3-and 5-component cascades.
For the 3-component cascade (Scheme 1), reaction of 8-fluoro--tetrahydrocarboline 7a or unsubstituted -tetrahydrocarboline 7b (1.0 mmol), with a series of aryl/heteroaryl iodides (0.98 mmol) and allene (0.5 atm), catalysed by Pd2(dba)3 (2.5 mol%) and tri-2-furylphosphine (TFP) (5 mol%) with caesium carbonate or potassium carbonate (2 mmol) as the base, gave the resulting adducts (8a-j) in 64-78 % yield (Table 1 , entries 1-10). All the cascades were regioselective in terms of producing products resulting from coupling at the aliphatic amine nitrogen. Additionally, we wished to explore the feasibility of incorporating biologically important building blocks into this sequence. Thus, an analogous cascade process involving reaction of 7a with aryl iodides and uridine-based allene (9) 15a (Scheme 2) was also investigated, which would give access to interestingly functionalised nucleoside analogues such as 10, (the predicted Z-stereochemistry within the alkene being based upon our previous observations 15b ), (Scheme 2).
Scheme 2: -tetrahydrocarboline 3-component cascade reaction using uridine allene 9.
The uridine allene 9 was readily prepared from uridine, 2',3',5'-triacetate via Npropargylation followed by homologation of the terminal alkyne using a cuprous bromide-catalysed reaction 16 with formaldehyde and diisopropylamine (DIPA) via a giving the uridine allene 9 in 55% yield (Scheme 2).
Compounds 10a-e were readily prepared from -carboline (7a) and uridine allene (9) 15a ( Table 2 , entry 1-5). a. 7a (1.0 mmol), Ar-I (0.98 mmol), Pd2(dba)3 (2.5 mol%)/ligand (5 mol%) base (2 mmol), MeCN (20 mL) at 80 °C for 3-7 h.
In order to further probe the range of structural diversity possible within this approach, a 5-component variant (defined in terms of utilising amine 7, plus two molecules each of allene and aryl iodide respectively), of the cascade reaction was investigated and a third series of analogues (Table 3 , entry 1-7) were prepared via 5-component cascades by using two equivalents of both aryl iodide and allene, with Cs2CO3 as base under similar reaction conditions to that used for the 3-component cascades already described (Scheme 3) . This cascade produced the anticipated products 11a-g along with the rearrangement products, pyrimidino[1, 6-a] indoles 12a-g, as an approximately 1:1 mixture of 11:12 type compounds (Table 3 , entries 1-7) in 48-66%
yield. The ratio of products within in each case was determined using 1 H-NMR analysis of the crude reaction mixtures, prior to isolation of the isomers using column chromatography .
Scheme 3: 5-Component cascade reaction.
The structures of the two reaction products were confirmed in the case of 11b and 12a via single crystal x-ray crystallography ( Figure 2 ). A mechanism is proposed (Scheme 4) for formation of 12. A palladium allyl coordinates to the indole double bond of the carboline and the indole lone pair triggers transfer of the allyl group to the 3-position of the indole to give intermediate A which initiates cleavage of the aliphatic ring to give B. Rotation of the iminium moiety facilitates ring closure with the indole nitrogen to give 12.
Scheme 4: Proposed mechanism of formation of 11a-g and 12a-g.
Protection of the aliphatic amine of 7 as the t-butyl carbamate derivative was investigated as a route to produce the -carboline product as opposed to the pyrimidino[1,6-a]indole rearrangement product. The BOC protected -carboline 13 was generated and successfully allylated at the 5-position giving 14a-e in 69-81% yield (Table 5 , entry 1-5) under similar reaction conditions to those previously described (Scheme 5) without formation of rearrangement product.
Scheme 5: Boc protection strategy for synthesis of substituted carbolines without formation of rearrangement products (Table 5 entries 1-3 ). An example of modification of the 5-position was also reported under smilar reaction conditions starting from 8d with 3-iodopyridine afforded 16c in 69% yield (Table 5 , entry 4).
The reactions gave exclusively the desired products (11b, 16a-c) in high yield. 
Biological testing
Three of the previously described -carbolines (8i, 8j and 16a) were biologically assessed for their potential as HDAC inhibitors. HDAC selectivity profiling was carried out by Scottish Biomedical (Table 6 ) using a fluorimetric assay. The compounds were preincubated with enzyme for a period of 24 hours and the screen was run in duplicate.
Compounds 8j and 16a, which both have a benzamide moiety as their zinc binding group, both displayed inhibition of HDAC3 and HDAC2 respectively. Compound 8i which possess a coumarin moiety in place of the benzamide group, showed no inhibitory effect on any of the HDACs tested. No inhibition of the HDAC1 isoform was observed. Compounds 8i and 16a were slightly more active against HDAC3 than HDAC2 and this, coupled with their lack of activity against HDAC1 indicates that it may be possible to develop these compounds into selective HDAC inhibitors. 
Conclusion
A series of allylic -carbolines have been synthesised via efficient 3-and 5-component palladium catalysed cascade reactions leading to the creation of a range of substituted carboline-based compounds, some of which were designed to be analogues of known antitumor agents proposed to act as HDAC enzyme inhibitors.
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These cascade reactions tolerate a broad range of substrates providing ready access to diversely substituted carboline scaffolds. Biological testing of a selected number of these systems showed inhibition of HDAC3 and HDAC2 for the most active compounds, indicating their potential as starting points for the development of future anticancer drugs.
Experimental
Column chromatography was performed on silica gel 60 (Merck, 230-400 mesh). 1 H NMR spectra were recorded at 500 MHz on a Bruker DPX500 instrument or at 300
MHz on a Bruker DPX300 instrument.
13
C NMR spectra were recorded at 75 MHz on a Bruker DPX300 instrument. All spectra were obtained for CDCl3 solutions unless stated otherwise. Chemical shifts are given in parts per million ( ) downfield from tetramethylsilane (0.00 ). Infra-red spectra were collected on a Perkin-Elmer Spectrum One FT-IR spectrometer. Samples were run as thin films on sodium chloride plates and were prepared by evaporation of a solution of compound in dichloromethane. Melting points were obtained on a Reichert hot-stage microscope and are uncorrected. Mass spectra were obtained on a Bruker, HCT-ultra (ES+).
Accurate masses were obtained using a Bruker Daltonics micrOTOF spectrometer.
Commercially available compounds were used as received. All compounds are named according to the IUPAC system; names were obtained using MDL Autonom.
General procedure A: 3-Component cascade.
Aryl iodide (1 mmol), nucleophile (0.8-1.2 mmol), tris-(2-furyl)-phosphine (TFP) (10 mol%), tris-dibenzylideneacetonedipalladium (0) (Pd2dba3) (2.5 mol%), base (2 mmol) and MeCN (20 mL) were combined in a Schlenk tube. After two freeze-pumpthaw cycles, allene gas (0.5 atm) was charged into the Schlenk tube, the mixture thawed and then heated for 16-24 h at 70-80°C with magnetic stirring. After cooling to room temperature and venting excess allene, DCM (10 mL) was added, the mixture filtered, and the filtrate evaporated in vacuo. Column chromatography of the residue afforded the product. 6, 140.3, 134.4, 132.4, 128.9 (2C), 127.6, 126.3 (d, J 9.0 
General

8-Fluoro
5-(3-(8-Fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-2(5H)-yl)prop-1-en-2-yl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (8g)
Prepared using 
4-iodo-N-(4-methyl-2-oxo-2H-chromen-7-yl) benzamide (8k)
A mixture of 4-iodobenzoic acid (1.00g, 4.03 mmol) and 7-amino-4-methyl coumarin (0.99 g, 5.64 mmol) in DMF (15 ml) was stirred at room temperature for 10 min. 4-(4,6-Dimethoxy-1,3,5-triazin-2yl)-4-methylmorpholin-4-ium chloride (1.12 g, 4.03 mmol) was added to the mixture and stirred at room temperature for 16.5 h. The mixture was quenched into water (50 ml) and extracted with ethyl acetate (3 x 15 ml), the combined organics were washed with aqueous sodium carbonate (1 x 10 ml), saturated ammonium chloride (1 x 10 ml) and brine (1 x 10 ml). 3, 147.6, 141.1, 138.7, 138.0, 132.8, 131.8, 131.6, 131.4, 130.7, 128.5, 125.4, 1βγ.5, 1ββ.1, 1β1.8, 1β1.4, 1β1.γ, 116.0, 11β.γ, 66.9, 55.0, 54.4, β8.6; max(film) 3370, 2988, 2305, 1915, 1787, 1694, 1681, 1618, 1588 
4-(3-
(
(2R,3R,4R,5R)-2-(acetoxymethyl)-5-(3-(buta-2,3-dienyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl diacetate (9) 15a
Propargyl bromide (1.1 ml, 10 mmol), (1.85 g, 5 mmol) and anhydrous potassium 170.5, 169.9, 169.8, 162.1, 150.7, 138.1, 102.8, 89.21, 86.0, 79.9, 77.5, 73.2, 70.2, 63.2, 39.4, 21.0, β0.8, β0.7; max(film) 2107, 1960, 1749, 1668, 1455, 1372, 1228 cm -1 . 2, 169.7, 162.1, 160.7, 159.7, 157.7 (d, J 234), 150.7, 142.1, 140.4, 137.4, 134.5, 132.4, 128.2, 127.3, 126.6, 126.4, 117.0 (d, J 8.5 ), 110.9 (d, J 9.7), 108.9 (d, J 25.9), 102.8 (d, J 23.8), 88. 6, 79.9, 79.7, 72.9, 70.0, 63.0, 56.2, 49.6, 49.4, 39.9, 23.8, 20.8, 20.5, 20.4; max(film) 169.7, 162.1, 157.6 (d, J 233.3), 150.7, 140.3, 139.1, 137.4, 137.0, 134.5, 132.4, 129.6, 128.9, 126.5, 126.4 (d, J 9.8), 125.6, 111.0 (d, J 9.8), 108.7 (d, J 26.2), 102.9, 102.7 (d, J 23.5), 88.5, 79.8, 72.9, 70.0, 63.0, 56.1, 49.7, 49.3, 39.9, 23.8, 21.1, 20.8, 20.5, 20.4; max(film) 3362, 3057, 2923, 1749, 1711, 1668, 1594, 1512, 1484, 1455, 1373, 1229 
(2R,3R,4R,5S)-2-(acetoxymethyl)-5-(3-((E)-4-(8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-2(5H)-yl)-3-(thiophen-2-yl)but-2-enyl)-2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)tetrahydrofuran-3,4-diyl diacetate (10d)
(2S,3R,4R,5R)-2-(3-((Z)-3-(4-(1H-pyrrol-1-yl)phenyl)-4-(8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-2(5H)-yl)but-2-enyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
5-(acetoxymethyl)tetrahydrofuran-3,4-diyl diacetate (10e)
Prepared using General Procedure B from 1-(4-iodophenyl)-1H-pyrrole (0. 6, 142.2, 140.5, 140.0, 137.4, 135.9, 135.9, 133.3, 127.6, 127.0, 126.4, 126.1 (d, J 9.8), 120.3, 120.1, 119.2, 119.2, 115.5, 112.7, 110.8, 110.5, 109.7 (d, J 9 2, 140.3, 138.8, 135.9, 133.2, 128.6, 128.3, 128.2, 127.6, 126.4, 126.1 (d, J 9.8), 125.9, 115.6, 112.7, 109.7 (d, J 9.8 
2,5-Bis(2-(4-(1H-pyrrol-1-yl)phenyl)allyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (11a) and 2,5-Bis(2-(4-(1H-pyrrol-1-yl)phenyl)allyl)-
8-Fluoro-2,5-bis(2-p-tolylallyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (11c) and
7-Fluoro-2,5-bis(2-p-tolylallyl)-1,2,3,4-tetrahydropyrimido[1,6-a]indole (12c)
Prepared using General Procedure C from iodotoluene (0. 3, 143.3, 138.0, 137.8, 137.4, 136.3, 136.2, 133.8, 129.4 142.7, 141.1, 140.82, 140.4, 140.4, 139.1, 137.6, 136.0, 133.3, 128.9, 128.8, 127.6, 127.3, 127.3, 127.1, 127.0, 126.9, 126.8, 126.2, 115.5, 112.6, 109.7 (d, J 9.8 145.7, 143.36, 140.7, 140.5, 140.2, 138.3, 134.8, 133.5, 131.6, 130.5, 129.0, 128.8, 128.6, 128.4, 127.4, 127.3, 127.1 (d, J 6.0), 127.0, 126.9, 126.7, 126.5, 125.4, 116.3, 113.3, 108.8 (d, J 9.8 Found: C, 59.95, H, 4.30, N, 4.70, Br, 27.65. C29H25Br2FN2 requires: C, 60.02, H, 4.34, N, 4.83, Br, 27.54) .
12e. H (300 MHz, CDCl3) 7.49-7.36 (m, 6H, aryl CH), 7.31 (d, 2H, J 8.6, aryl CH), 7.14 (dd, 1H, J 9.8, 2.4, aryl CH), 7.06 (dd, 1H, J 8.8, 4.3, aryl CH), 6.85 (ddd, 1H, J 9.1, 9.0, 2.4, aryl CH), 5.54 (s, 1H, allyl CH), 5.34 (d, 1H, J 0.7, allyl CH), 5.22 (s, 1H, allyl CH), 4.98 (s, 1H, J 0.7, allyl CH), 4.79 (s, 2H, alkyl CH2), 3.76 (s, 2H, alkyl CH2), 3.61 (s, 2H, alkyl CH2), 3.08 (t, 2H, J 6.2, alkyl CH2), 2.85 (t, 2H, J 6.2, alkyl CH2); C 157.9 (d, J 234.0), 145.2, 142.9, 140.4, 138.3, 133.4, 131.57, 131.5, 131.3, 128.6 (d, J 9.8), 128.0 (s, 2C), 127.8 (s, 2C), 121.9, 121.4, 116.8, 113.9, 108.8 (d, 10.2), 108.5 (d, J 26.6), 107.4 (d, J 4.7), 103.4 (d, J 23.6), 63.3, 56.6, 47.1, 29.8, 19.3; max(film) 3392, 3022, 2900 , 2651 , 2351 , 1624 , 1579 , 1488 Found: C, 59.80, H, 4.30, N, 4.75, Br, 27.75. C29H25Br2FN2 requires: C, 60.02, H, 4.34, N, 4.83, Br, 27.54 ). 11f. H (300 MHz, CDCl3) 7. 6H, aryl CH), 7.26 (d, 2H, J 8.6, aryl CH), 7.10 (dd, 1H, J 9.7, 2.4, aryl CH), 7.06 (dd, 1H, J 8.8, 4.3, aryl CH), 6.86 (ddd, 1H, J 9.1, 9.0, 2.4, aryl CH), 5.53 (s, 1H, allyl CH), 5.33 (s, 2H, allyl CH), 4.89 (s, 2H, alkyl CH2), 4.46 (s, 1H, allyl CH), 3.71 (s, 2H, alkyl CH2), 3.59 (s, 2H, alkyl CH2), 2.89 (t, 2H, J 5.5, alkyl CH2), 2.68 (t, 2H, J 5.5, alkyl CH2); C 157.7 (d, J 233.9), 145.7, 145.5, 143.3, 133.8, 132.0, 129.7 (2C) 128.3 (2C), 127.6 (2C), 127.1 (2C), 125.6 (d, J 9.0), 125.4, 124.3, 117.6, 116.1, 109.7, 109.2, 109.1 (d, J 10.0), 107.8 (d, J 24.5), 107.3 (d, J 4.5), 103.8 (d, J β4.5), 6β.7, 57.γ, 47.4, γ1.β, β1.γ; max(film) 3081, 2920, 1948, 1818, 1630, 1583, 1471, 1318 12f. H (C6D6, 500 MHz) 7.62 (d, J 8.3, 2H, aryl CH), 7.54 (m, 4H, aryl CH), 7.48, (d, 2H, J 8.3, aryl CH), 7.15 (dd, 1H, J 9.7, 2.4, aryl CH), 7.07, 6.86 (ddd, 1H, J 9.1, 8.9, 2.5, aryl CH), (dd, 1H, J 8.8, 4.3, aryl CH), 5.61 (s, 1H, allyl CH), 5.40 (s, 1H, allyl CH), 5.30 (s, 1H, allyl CH), 5.10 (d, 1H, J 0. 9, allyl CH), 4.81 (s, 2H, alkyl CH2), 3.80 (s, 2H, alkyl CH2), 3.65 (s, 2H, alkyl CH2), 3.10 (t, 2H, J 6.1, alkyl CH2), 2.86 (t, 2H, J 6.1, alkyl CH2); C 157.5 (d, J 234), 145.7, 145.5, 143.3, 133.8, 132.0, 129.4 (2C) 128.8 (2C), 127.0 (2C), 126.9 (2C), 125.8 (d, J 9.0), 125.7, 125.6, 118.6, 115.6, 109.3, 109.2, 108.9 (d, J 10.0), 107.7 (d, J 24.5), 107.4 (d, J 4.5), 104.0 (d, J 24.5), 6γ.7, 57.0, 47.6, γβ.0, β0.γ; max(film) 3083, 2920, 1948, 1818, 1630, 1583, 1471, 1318 cm -1 ; m/z (ES + ) 559.2 (100%, MH + ); (Found: C, 66.60, H, 4.45, N, 4.95 C31H25F7N2 requires: C, 66.66, H, 4.51, N, 5.02 ). 3.78 (s, 3H, alkyl CH3), 3.73 (s, 2H, alkyl CH2), 3.59 (s, 2H, alkyl CH2), 2.90 (t, 2H, J 5.4, alkyl CH2), 2.70 (t, 2H, J 5.4, alkyl CH2); C 159.6, 159.1, 157.7 (d, J 225.1), 143.8, 142.4, 136.0, 133.2, 132.7, 131.2, 127.5, 126.9, 126.1 (d, J 9.9), 114.0, 113.8, 113.6, 111.0, 109.7 (d, J 9.8), 108.7 (d, J 25.9), 108.4 (d, J 4.6), 102.8 (d, J βγ.5), 6β.β, 55.4, 55.γ, 49.8, 49.6, 46.4, ββ.6; max(film) 3696, 3155, 2902, 2839, 2253, 1793, 1654, 1606, 1512, 1466 155.4, 134.2, 132.5, 125.8 (d, J 9.9), 111.4 (d, J 9.4), 109.4 (d, J 26.0), 107.3, 102.7 (d, J βγ.5), 80.γ, 41.4, 40.7, β8.6 (γC), βγ.6; max(film) 3337, 3233, 2992, 2492, 2214, 2072, 1944, 1733, 1407 4, 47.7, 4β.9, 4β.0, β0.7; max(film) 3485, 3270, 3006, 2250, 2124, 1667, 1626, 1476, 1364, 1151 141.72, 141.25, 139.85, 136.19, 133.69, 133.57, 126.67, 126.65, 126.44, 125.33, 123.72, 121.94, 115.33, 114.44, 110.04 (d, J 10.0 
8-Fluoro
